Nps Pharmaceuticals, Inc.

The Brigham and Women's Hospital, Inc.

University of Minnesota

Astrazeneca Ab

Manuel F. Balandrin

Bradford C. Van Wagenen

Richard Trovato

Scott T. Moe

Eric G. Delmar

Abdelmalik Slassi

Susan M. Sheehan

Donald A. Mcleod

Daryl L. Smith

Thomas M. Stormann

Methvin Benjamin Isaac

Scott T Moe

Manuel F Balandrin

Bradford C Van Wagenen

Eric G DelMar

Alan L Mueller

Daryl Lynn Smith

Robert M Barmore

Linda D Artman

Thomas M Stormann

Bradford C VanWagenen

Edward F Nemeth

Susan M Sheehan

Ruth J Walton

Donald A McLeod

Eric Delmar

Irina V Shcherbakova

Louise G Edwards

Tao Xin

Philip S Portoghese

Ian Egle

Jalaj Arora

Tomislav Stefanac

William Michne

Richard Travato

Shigenori Ohkawa

Bradford Van Wagenen

Daryl L Smith

Donald A Mcleod

Eric G Delmar

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases

The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders using such compounds. Preferred compounds can mimic or block the effect of extracellular calcium on a cell surface calcium receptor.

Inorganic ion receptor-active compounds

Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacological half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their uses

Inorganic ion receptor active compounds

Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.

The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca,on a calcium receptor.

Calcium receptor-active compounds

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hyproxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

Compounds active at a novel site on receptor-operated calcium channels

Growing community of inventors

Salt Lake City, UT, United States of America

Scott T Moe